Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Journal of Hematology & Oncology|October 1, 2017
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesSrdan Verstovsek, Jason Gotlib, Ruben A Mesa, et al.The Lancet. Oncology|June 30, 2014
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Christophe Massard, Petri Bono, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126Jeffrey L Evelhoch, Patricia M LoRusso, Zhanquan He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancerEmer O Hanrahan, Heather Y Lin, Edward S Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialSamuel A Wells, Bruce G Robinson, Robert F Gagel, et al.The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerRonald B Natale, Sumitra Thongprasert, F Anthony Greco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20Andrew M Arnold, Lesley Seymour, Michael Smylie, et al.Pageof 3